![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 12")
The DEA’s June 29 Hearing Explained: What Full Cannabis Rescheduling Would Mean for Medical Patients
A federal DEA hearing beginning June 29, 2026 will determine whether all cannabis — not just state-licensed medical marijuana — moves from Schedule I to Schedule III. Medical cannabis patients need to understand what the April order already changed, what this hearing is actually deciding, and what would follow if broader rescheduling goes through.
Table of Contents
The DEA’s June 29 Hearing Explained: What Full Cannabis Rescheduling Would Mean for Medical Patients
We have already covered what the April 28 rescheduling of state-licensed medical cannabis meant. This post is about something different: the DEA hearing that starts June 29 and runs through July 15, 2026, in which an administrative law judge will hear arguments on whether to move all forms of marijuana — state-licensed medical, recreational, and federally unregulated — into Schedule III. That is a much larger question, and the outcome will shape cannabis medicine’s legal foundation for the next generation.
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →This hearing directly shapes the legal framework for every medical cannabis patient in the United States. A full Schedule III outcome would open insurance reimbursement pathways, allow physician prescribing under federal law, and dramatically expand clinical research infrastructure — the most consequential federal cannabis event in more than fifty years.
- What the April 28 order already changed — and what it left untouched
- What the June 29 DEA hearing is specifically deciding and how
- What full Schedule III rescheduling would mean for patients, providers, and research
- What remains legally unresolved even if the broader rescheduling goes through
- What the timeline looks like and what patients should actually do right now
❇ The April 28 DEA order moved state-licensed medical cannabis to Schedule III immediately. That is already in effect.
❇ The June 29 hearing will decide whether ALL cannabis — including recreational — moves to Schedule III through formal rulemaking. That outcome is not predetermined.
❇ If full rescheduling proceeds, the pathway opens for insurance reimbursement, physician prescribing under federal law, and dramatically expanded clinical research.
❇ Even after full rescheduling, significant FDA questions around cannabis foods and supplements remain unresolved.
Cannabis has been a Schedule I controlled substance since 1970 — classified alongside heroin, above cocaine, on the basis of claimed “no accepted medical use.” That classification made it federally illegal for any physician to prescribe, created nearly insurmountable barriers for clinical research, and excluded every form of cannabis from any pathway toward insurance coverage. More than fifty years of patients were left to navigate an evidence gap that was created by law, not by science.
The April 28 order broke the dam for state-licensed medical cannabis. The June 29 hearing is about whether the entire body of water moves. If the administrative law judge recommends full Schedule III rescheduling and the acting attorney general accepts, the federal barrier that has defined cannabis medicine’s limitations for half a century dissolves. That is why this hearing is historic regardless of its outcome.
On April 23, 2026, Acting Attorney General Todd Blanche announced an order placing two categories of marijuana in Schedule III of the Controlled Substances Act: FDA-approved drug products containing cannabis, and cannabis products subject to a qualifying state medical marijuana license. This took effect April 28, 2026. The legal mechanism used was the Attorney General’s authority to align DEA scheduling with U.S. treaty obligations under the 1961 UN Single Convention on Narcotic Drugs — an approach that allowed the change to take immediate effect without the standard notice-and-comment rulemaking process. This followed President Trump’s Executive Order 14370, issued December 18, 2025, directing the expedited rescheduling of cannabis.
The June 29 hearing is a separate, formal administrative proceeding. It begins at the DEA Hearing Facility in Arlington, Virginia, and runs through July 15, 2026. It will consider whether all forms of marijuana — recreational cannabis, unlicensed marijuana, and cannabis not covered by a state medical license — should be rescheduled from Schedule I to Schedule III through formal federal rulemaking. This proceeding replaces the prior hearing process initiated August 2024, which was stayed January 2025 and subsequently withdrawn. DEA’s previous sole ALJ retired in July 2025; a new administrative law judge designated by Acting AG Blanche will preside.
Even a favorable full Schedule III outcome leaves substantial legal territory unsettled. The Federal Food, Drug, and Cosmetic Act prohibits the sale of unapproved drug products, and FDA has taken the position that products containing THC cannot lawfully be sold as foods or dietary supplements. The April 28 rescheduling order explicitly did not address this. FDA has not issued any guidance on how rescheduling affects its posture toward the thousands of commercial cannabis products currently sold in dispensaries, health food stores, and online.
A related complication: the hemp definition under the 2018 Farm Bill is set to narrow in November 2026. Under the terms of a continuing resolution passed in November 2025 (H.R. 5371), CBD products containing more than 0.3% THC will be reclassified as marijuana from November 2026 onward. This directly affects a broad range of products currently sold as hemp-derived CBD. Neither the April 28 order nor the June 29 hearing fully resolves how those products are treated. Patients and providers need to track both timelines.
How This Fits With the Broader Clinical Conversation
Cannabis medicine has operated inside a federal legal contradiction for more than five decades. States built medical programs. Patients enrolled. Physicians certified. Dispensaries opened. None of it ever rested on solid federal ground. The April 28 order changed that for the first time. State medical cannabis programs are now explicitly recognized as lawful under federal law — not merely tolerated through enforcement discretion. That shift carries real weight for providers with DEA registrations, for insurers watching the regulatory landscape, and for researchers who need access to federally legal study material.
In Massachusetts, where CED Clinic operates, the practical changes are real but still taking shape. Dispensaries holding state medical licenses now operate under Schedule III federal law. They can in principle obtain DEA registrations and satisfy federal controlled substance tracking requirements. If the June 29 hearing results in full Schedule III rescheduling, the implications for research universities and academic medical centers in Boston and Cambridge would be substantial. Clinical trials that were previously impossible to fund through conventional channels become realistic. Drug interactions involving cannabis can be studied the way drug interactions involving other Schedule III medications are studied today.
At the same time, the clinical evidence base for cannabis medicine does not change on the day of a federal ruling. What the hearing outcome changes is what research is possible, what physicians can do under federal law, and whether insurance reimbursement pathways open. It does not validate or invalidate the evidence already in hand — and it does not resolve the dosing, formulation, and patient selection questions that every practicing cannabis physician navigates in every clinical encounter.
The hearing also does not answer what happens next on the FDA side. The agency has historically used enforcement discretion to avoid shutting down the commercial cannabis industry while formally maintaining that THC-containing products violate the FDCA outside of approved drug pathways. That posture becomes harder to sustain if full Schedule III rescheduling goes through. Expect FDA to face significant pressure to issue guidance, likely in late 2026 or 2027.
“I have practiced cannabis medicine long enough to remember when this conversation felt entirely theoretical. The April 28 order was not theoretical. For the first time in my career, the federal government has explicitly recognized what state medical programs have built — and what my patients have relied on. That recognition matters, even knowing that recognition and resolution are not the same thing.
“What I am watching in the June 29 hearing is not the political headline but the administrative process. The mechanism here — formal federal rulemaking with an ALJ, an expedited timeline, firm deadlines — is a different structure from the five years of proposed rules and stayed hearings that preceded it. Whether the outcome is full Schedule III rescheduling or a narrower recommendation, this process is more legally durable than anything cannabis policy has had at the federal level before. My patients are asking me what to do with this news. My honest answer: nothing changes in your clinical care today. But if you have been waiting for a credible sign that the federal landscape is genuinely shifting, this is the most substantial signal I have seen in twenty years of practicing this medicine.”
What a Careful Reader Should Take Away
The April 28 order is already in effect. State-licensed medical cannabis is now a Schedule III controlled substance under federal law. CED Clinic covered what this means for research access and patient care in prior posts — the links are in the Related Reading section below.
The June 29 hearing is a separate proceeding that may extend those changes to all cannabis — or may not. The outcome is not predetermined. The ALJ process is formal, with legal representation, a hearing record, and an administrative timeline. A recommendation for full Schedule III rescheduling is plausible and aligned with current federal policy direction, but it is not guaranteed, and any outcome will likely face legal challenges.
For patients at CED Clinic, the most important thing to understand is this: your access to medical cannabis through a state-licensed program is more federally secure today than it has ever been. What the June 29 hearing determines is how much further federal law is willing to go — and how quickly the remaining legal infrastructure catches up to fifty years of patient reality.
The Same Federal Ruling Can Mean Different Things Depending on Who Is Reading It
The June 29 DEA hearing is simultaneously a legal proceeding, a clinical policy event, a public health decision, and a political moment. Patients, clinicians, researchers, legal observers, and policy critics will read the same process and outcome very differently. The perspectives below explore those readings.
Patient Takeaway
If you are a medical cannabis patient in Massachusetts or another state with a licensed medical program, your situation improved meaningfully on April 28, 2026. For the first time in more than fifty years, the federal government has explicitly acknowledged that what you are doing — accessing cannabis through a state-licensed dispensary under physician certification — is no longer a Schedule I federal violation. That is not a small change. It means the legal ground under your medical cannabis use is more stable than it has ever been.
The June 29 hearing is about something larger: whether everyone else gets that same federal recognition, including people in states without medical programs and people who use cannabis for adult use. If the ALJ recommends full Schedule III rescheduling, the practical implications for you personally are significant over time. Insurance companies could begin covering cannabis-based treatments that are currently out-of-pocket. Physicians who have been reluctant to certify or recommend cannabis because of federal law concerns may become more willing. Research into formulations, dosing, and specific conditions you care about would accelerate.
For now: your access to medical cannabis through CED Clinic and a licensed Massachusetts dispensary continues exactly as before. Nothing has changed in how you obtain your medication, how you use it, or how it is recommended. What has changed is the legal context in which all of that happens — and that context is more favorable than it has ever been.
Clinician’s POV
From a practicing physician’s perspective, the April 28 order resolves one long-standing tension and creates a new set of practical questions. The resolved tension: physicians who hold DEA registrations no longer risk federal enforcement conflict when certifying patients for state medical cannabis programs. That conflict was largely theoretical in recent years given the Rohrabacher-Blumenauer appropriations rider, but theoretical conflicts still affect clinical behavior. Explicit Schedule III status removes the ambiguity.
The new questions are operational. The DEA order establishes new registration requirements for dispensaries and manufacturers under state medical licenses. Practitioners who want to engage more formally with cannabis — writing prescriptions rather than certifications, accessing cannabis through DEA-registered channels rather than state-licensed dispensaries — will need to understand the new registration framework as it develops. That framework is still being built. The June 29 hearing outcome determines whether the same framework eventually extends to all cannabis or remains limited to state medical programs.
The research implications are the most directly relevant to clinical practice. Schedule III classification removes the DEA licensing barriers that previously prevented academic medical centers from conducting cannabis research under the same regulatory framework as other controlled substance research. That will eventually produce better clinical evidence. For now, the existing evidence base — which already supports cannabis for pain, sleep, anxiety, nausea, and several neurological conditions — is unchanged and should continue to guide clinical decision-making.
A Skeptical Read
A careful skeptic notes that the legal mechanism used for the April 28 order — the Attorney General’s authority under the Single Convention on Narcotic Drugs — has not been tested in court. The argument that the treaty allows an immediate, no-notice rescheduling of cannabis is legally creative. Courts have not reviewed it. Legal challenges to the order have been signaled by several advocacy groups on the grounds that the conventional rescheduling process under the Controlled Substances Act requires notice, comment, and scientific findings that were bypassed here. If a legal challenge succeeds, the April 28 order could be vacated.
The June 29 hearing, as a formal rulemaking process, is more legally conventional and therefore more durable. But the outcome is not guaranteed, and administrative law proceedings can be challenged. The history of cannabis rescheduling proceedings at the federal level is a history of delay, reversal, and political interference. The 2024 proposed rulemaking was followed by a stayed hearing and the retirement of the only DEA ALJ. The prior administration’s rescheduling effort took years and ultimately was not completed. This administration’s timeline is faster, but the legal landscape can change.
Process Critic
The most substantive process criticism of the April 28 order is the use of the treaty authority mechanism to bypass standard rulemaking. The Controlled Substances Act requires the Attorney General to request a scientific and medical evaluation from the Secretary of Health and Human Services before rescheduling, and to make findings about abuse potential, medical utility, and dependence liability. That process was used for the proposed 2024 rulemaking, which produced an HHS recommendation and a formal proposed rule. The April 28 order skipped that process for the treaty-authority portion of the rescheduling.
A secondary process criticism concerns the withdrawal of the prior hearing and the starting over with a new ALJ and new proceedings. The 2024 hearing process involved many participants who had already prepared submissions. The decision to terminate those proceedings and begin a new process — even an expedited one — reset the clock and created uncertainty for parties who had invested in the prior process. Whether the expedited timeline compensates for this disruption is a legitimate question, particularly for advocacy groups and public health organizations who were prepared to participate in the prior process.
Compared to Past Policy
Federal cannabis policy has been defined by a recurring gap between medical reality and federal law. The first formal petition to reschedule cannabis was filed in 1972, two years after the Controlled Substances Act was enacted. The DEA denied that petition in 1989 after seventeen years of administrative proceedings. Subsequent petitions in the 1990s and 2000s were similarly denied. The 2016 DEA review again found that cannabis did not meet the criteria for rescheduling, citing insufficient clinical evidence — evidence that was itself unavailable precisely because Schedule I classification prevented the research that would have generated it.
The 2024 proposed rule was the first time HHS formally recommended rescheduling and the DEA initiated a rulemaking process. That process was stayed, and its ALJ retired. The April 2026 order and June 29 hearing represent a third pathway — direct executive action for immediate partial rescheduling plus a new, expedited rulemaking for broader action. No prior federal administration has used all three levers simultaneously. In that sense, the current approach is genuinely without historical precedent. The timeline is also without precedent: the 1972 petition took 17 years. The 2024 proposed rule took less than 18 months to reach the administrative hearing stage, and the June 29 hearing must conclude by July 15. Whether speed in the administrative process produces durable policy is a question the historical record does not yet answer.
Practical Considerations
For dispensaries holding state medical licenses, the April 28 order creates a new requirement: obtaining DEA registration to continue operating under federal law. The DEA order requires registration but also creates an expedited process for granting it to applicants who already hold state medical licenses. The practical implications — what registration requires, what record-keeping and reporting it entails, how it interacts with state licensing — are still being worked out in new DEA regulations. Dispensaries should be consulting legal counsel who specialize in controlled substances law.
For patients, the most immediate practical question is whether the April 28 rescheduling changes anything about purchasing or possessing state-licensed medical cannabis. The short answer is no, not yet. State programs continue to operate under state law, and the new DEA registration requirements are not yet in full effect. The June 29 hearing outcome does not create or eliminate any patient rights. What it could do, over a period of months to years, is open insurance coverage discussions and research funding that eventually translates into better clinical options and lower out-of-pocket costs.
The November 2026 hemp definition change is a separate practical concern. Patients using CBD products that contain more than 0.3% THC — including many full-spectrum products currently sold as hemp-derived — should be aware that those products will be reclassified as marijuana under federal law from November 2026 onward, unless FDA takes action to address the regulatory gap before then.
Future Directions
The most significant near-term unknowns after the June 29 hearing are: (1) what recommendation the ALJ makes and how quickly the Acting Attorney General acts on it; (2) whether courts accept or invalidate the treaty-authority mechanism used for the April 28 order; and (3) what FDA does about the regulatory gap for cannabis-containing foods, supplements, and unapproved drug products. All three timelines could run in parallel, and the outcomes could conflict with each other.
If full Schedule III rescheduling goes through in 2026, the next major federal cannabis policy event is likely an FDA action addressing commercial cannabis products — either formal guidance, proposed regulations, or an enforcement action that forces a legal ruling. That process could take years and would itself be subject to legal challenge. The November 2026 hemp definition change also creates a potential flashpoint if FDA does not clarify its posture on CBD products containing THC before then.
From a research perspective, even an optimistic scenario takes several years to produce meaningful new clinical evidence. The regulatory pathway for cannabis research under Schedule III will need to be operationalized by DEA and FDA. Institutional review boards will need to update their cannabis research policies. Grant funding agencies — NIH in particular — will need to revise the guidance that has historically discouraged cannabis research funding. These institutional changes do not happen the month after a rescheduling order. A realistic timeline for the first wave of high-quality clinical trials enabled by Schedule III status is 2028 to 2030.
Misreadings & Bad-Faith Takes
“Cannabis is now federally legal.” This is the most common misreading and the most consequential one for patients. The April 28 order rescheduled state-licensed medical cannabis and FDA-approved cannabis products from Schedule I to Schedule III. Schedule III is still a controlled substance classification. Cannabis is not federally legal in the way that alcohol and tobacco are legal. It cannot be purchased across state lines. It cannot be transported on federally regulated transportation without violating federal law. It cannot be possessed at federal facilities. The change is significant, but it is not legalization.
“This means your dispensary can now take insurance.” Insurance reimbursement for cannabis is not a direct consequence of Schedule III rescheduling. Insurance coverage requires either federal mandate or voluntary insurer action, and neither is automatic or immediate. Some insurers may begin exploring reimbursement pathways for FDA-approved cannabis products — Epidiolex, dronabinol — but the broader commercial cannabis market remains well outside standard insurance structures. This will take years, if it happens at all under current federal policy.
“The recreational cannabis industry is now federally legal.” Recreational cannabis in adult-use states remains Schedule I until and unless the June 29 hearing results in full rescheduling and that rescheduling survives legal challenge. Even then, the recreational industry would be moving to Schedule III — still regulated, still requiring DEA registration, still subject to federal controlled substance requirements. The headline “cannabis federally legal” significantly overstates what both the April 28 order and the June 29 hearing could produce.
“Your doctor can now prescribe cannabis.” Prescribing a controlled substance requires an FDA-approved drug application for that specific product and indication. Cannabis without an FDA-approved application cannot be prescribed under federal law regardless of scheduling. Physicians can certify patients for state medical programs, and they always could. What Schedule III status may eventually enable is an expanded set of FDA-approved cannabis-based drugs that can be prescribed — but those products must go through the full approval process first.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
U.S. Department of Justice, Office of Public Affairs. “Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III.” Press Release 26-392. April 23, 2026. justice.gov
Drug Enforcement Administration. “Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III.” Final rule. 91 Fed. Reg. 22714 (April 28, 2026). Federal Register
Gibson, Dunn & Crutcher LLP. “DEA Downschedules State Medical Marijuana to Schedule III; Expedited Hearing Set to Consider Broader Rescheduling.” Client Alert. April 29, 2026. gibsondunn.com
Frequently Asked Questions
What does the April 28, 2026 DEA order actually change for medical cannabis patients?
The April 28 order moved state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective immediately. This is the first time federal law has explicitly recognized state medical cannabis programs as lawful. In practical terms, it reduces the federal enforcement risk for patients, providers, and dispensaries operating under a state medical license. It does not change how you obtain, use, or pay for your medication today — those processes continue exactly as before through your state’s medical cannabis program.
What is the June 29 DEA hearing actually deciding?
The June 29 hearing is a formal administrative proceeding to determine whether all forms of marijuana — including recreational cannabis in adult-use states, unlicensed marijuana, and cannabis not covered by a state medical license — should be rescheduled from Schedule I to Schedule III through formal federal rulemaking. This is separate from and goes beyond the April 28 order, which only covered FDA-approved cannabis products and state-licensed medical marijuana.
Is cannabis federally legal after the April 28 rescheduling?
No. Schedule III is still a controlled substance classification under the Controlled Substances Act. Cannabis is not federally legal in the way alcohol and tobacco are legal. It cannot be transported across state lines, purchased at federal facilities, or possessed in federally regulated spaces without violating federal law. The April 28 order makes state-licensed medical cannabis explicitly lawful under federal law, but it does not make cannabis broadly legal at the federal level.
Will insurance cover cannabis if full Schedule III rescheduling goes through?
Not automatically, and not immediately. Insurance coverage for cannabis is not a direct legal consequence of Schedule III rescheduling. Coverage requires either a federal mandate or voluntary insurer action. Some insurers may explore coverage for FDA-approved cannabis-based drugs, but the broader commercial cannabis market is likely to remain outside standard insurance structures for years even under full Schedule III. This is a longer-term policy development, not an immediate change.
Can my doctor now prescribe cannabis instead of certifying me?
No. Prescribing a controlled substance requires an FDA-approved drug application for the specific product and indication. Cannabis without an FDA-approved application — which describes nearly all commercially available cannabis — cannot be prescribed under federal law regardless of its scheduling. Physicians can continue to certify patients for state medical programs, as they have been doing. What Schedule III status eventually enables is an expanded set of FDA-approved cannabis-based drugs that can be prescribed — but those products must complete the full FDA approval process first.
What happens to CBD products if the hemp definition changes in November 2026?
Under the terms of the continuing resolution passed in November 2025 (H.R. 5371), the legal definition of hemp will narrow in November 2026. CBD products containing more than 0.3% THC will be reclassified as marijuana rather than hemp. This affects a significant segment of the current hemp-derived CBD market, including many full-spectrum products. Patients using these products should be aware of this timeline and consult with their physician about how it may affect their options. Neither the April 28 order nor the June 29 hearing directly resolves how these products are regulated.
How long has the federal rescheduling process been underway?
The first formal petition to reschedule cannabis was filed in 1972, two years after the Controlled Substances Act was enacted. The DEA denied it in 1989 after seventeen years of administrative proceedings. Subsequent petitions were denied in the 1990s and 2000s. The first HHS recommendation for rescheduling came in 2024, leading to a proposed rule. That hearing process was stayed in January 2025 after the sole DEA ALJ retired. The April 2026 order and June 29 hearing are the most concrete federal rescheduling actions in the more than fifty-year history of the effort.
What would full Schedule III rescheduling mean for cannabis research?
Schedule III classification would remove the DEA licensing barriers that have historically prevented academic medical centers from conducting cannabis research on the same basis as research on other controlled substances. Researchers would no longer need a separate Schedule I researcher registration to study cannabis. This would make cannabis clinical trials easier to fund, conduct, and publish. However, a realistic timeline for the first wave of high-quality new clinical trials enabled by Schedule III status is 2028 to 2030 — institutional and funding changes take time even after the legal barrier is removed.
Could the April 28 rescheduling order be reversed?
It is possible. The legal mechanism used — the Attorney General’s authority under the 1961 UN Single Convention on Narcotic Drugs — bypassed the conventional notice-and-comment rulemaking process. This approach has not been tested in court. Legal challenges have been signaled by some advocacy groups. If a court vacates the order, the April 28 rescheduling would be undone pending a formal rulemaking process. The June 29 hearing, by contrast, follows conventional administrative rulemaking procedures and would be more legally durable if challenged.
What should I do right now as a CED Clinic patient?
Nothing changes in your clinical care today. Continue using your medical cannabis under your existing state certification and through your state-licensed dispensary. If you have questions about how these federal changes affect your specific situation — your DEA registration as a provider, your research participation, or your product choices given the November 2026 hemp reclassification — bring those questions to your next appointment. The legal landscape is shifting in a favorable direction for medical cannabis patients, but the most important foundation of your care remains your individualized clinical relationship and a state program that has been building evidence and infrastructure for years.
